Conferences - Results from #7300

FOIU 2018: Active Surveillance for Intermediate Risk Prostate Cancer - FOR July 8, 2018

FOIU 2018: Can MRI Replace Biopsy in Men on Active Surveillance? - YES July 8, 2018

FOIU 2018: Can MRI Replace Biopsy in Men on Active Surveillance? - NO July 8, 2018

FOIU 2018: Proper Selection of Patients for Active Surveillance – Primum Non Nocere? July 8, 2018

FOIU 2018: Active Surveillance In Young Men July 8, 2018

FOIU 2018: Critical Role of Pathology for Active Surveillance Criteria and Definition of “Progression” July 8, 2018

FOIU 2018: A PSA Threshold of 1.5 ng/ml for Further Diagnostic Tests - AGAINST July 8, 2018

FOIU 2018: A PSA Threshold of 1.5 ng/ml for Further Diagnostic Tests - FOR July 8, 2018

FOIU 2018: Intermediate Risk Prostate Cancer Case with a 1 cm PZ Lesion on MRI - What is the Preferred Treatment? July 8, 2018

FOIU 2018: Evidence and Anecdotal Based Approach for High-Risk Bladder Cancer: Is Bladder Preservation an Option? A Tale of Two Cities July 7, 2018

FOIU 2018: Trimodal Therapy for Muscle Invasive Bladder Cancer July 7, 2018

FOIU 2018: Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitors Era: The CARMENA Study July 7, 2018

FOIU 2018: Robotic Assisted Radical Cystectomy July 7, 2018

FOIU 2018: Prostate Sparing Cystectomy: Functional and Oncological Results July 7, 2018

FOIU 2018: Statin Use in Prostate Cancer July 6, 2018

FOIU 2018: Agonists vs. Antagonists: Should Antagonists be the Primary Choice for ADT? - YES July 6, 2018

FOIU 2018: Agonists vs. Antagonists: Should Antagonists be the Primary Choice for ADT? - NO July 6, 2018

FOIU 2018: Intermittent vs. Continuous ADT July 6, 2018

FOIU 2018: Is there a "Cardio-friendly" ADT? July 6, 2018

FOIU 2018: Epidemiology: The RADICAL PC Trial July 6, 2018

Page 366 of 594